Biocartis Group NV Logo

Biocartis Group NV

BCART | BR

Overview

Corporate Details

ISIN(s):
BE0974281132 (+1 more)
LEI:
549300J4HOJL5KG8HY54
Country:
Belgium
Address:
GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
Sector:
Health Care
Industry:
Health Care Providers & Services

Description

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis. Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-01-10 00:00
Regulatory News Service
BIOCARTIS GROUP NV 2024-01-05 to Issuer (JPM).pdf
English 219.7 KB
2024-01-10 00:00
Major Shareholding Notification
20240110_Share treshold notification_JPM_ENG.pdf
English 103.6 KB
2023-10-03 07:00
Declaration of Voting Results & Voting Rights Announcements
JJDC - Biocartis - Transparency Notification Form - Final - 27 September 2023 -…
English 514.6 KB
2023-10-03 07:00
Regulatory News Service
20231003_PR TranspNotification_JJDC_ENG.pdf
English 73.0 KB
2023-10-03 07:00
Major Shareholding Notification
20231003_PR TranspNotification_JJDC_NL.pdf
Dutch 74.8 KB
2023-09-26 07:00
Regulatory News Service
MASTER Biocartis H1 2023 Financial Report ENG_FINAL.pdf
English 8.2 MB
2023-09-26 07:00
Regulatory News Service
Biocartis H1 2023 Financial Report NLD_FINAL.pdf
Dutch 9.5 MB
2023-09-26 07:00
Earnings Release
20230926 PR H1 2023 Results_ENG.pdf
English 203.5 KB
2023-09-26 07:00
Earnings Release
20230926 PR H1 2023 Results_NL.pdf
Dutch 204.9 KB
2023-07-18 07:00
Board/Management Change
20230718_cfo_announcement_eng.pdf
English 112.3 KB
2023-07-18 07:00
Board/Management Change
20230718_cfo_announcement_nl.pdf
Dutch 75.5 KB
2023-06-30 07:00
Major Shareholding Notification
pr_outstanding_shares_june2023_eng.pdf
English 109.9 KB
2023-06-30 07:00
Declaration of Voting Results & Voting Rights Announcements
pr_outstanding_shares_june2023_nl_1.pdf
Dutch 114.9 KB
2023-06-20 17:40
Major Shareholding Notification
230619_pr_transpnotification_ubs_eng.pdf
English 74.9 KB
2023-06-20 17:40
Major Shareholding Notification
230619_pr_transpnotification_ubs_nl.pdf
Dutch 93.3 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2021-04-29 Devogelaere Benoit Executive member Buy 15,000 N/A
2021-04-28 Marcofin BV Executive member Buy 30,000 N/A
2021-04-27 Herman Verrelst Board Buy 60,000 N/A
2020-11-13 Devogelaere Benoit Executive member Buy 50,000 N/A
2020-05-06 Herman Verrelst Board Buy 50,000 249,625.00 EUR
2020-05-06 Herman Verrelst Board Buy 300,000 N/A
2020-05-04 Herman Verrelst Board Buy 46,803 231,656.00 EUR
2020-05-04 Herman Verrelst Board Buy 3,197 15,315.00 EUR
2019-12-18 Devogelaere Benoit Executive member Buy 50,000 N/A
2019-12-16 Welten Ewoud Executive member Buy 10,000 N/A

Peer Companies